🇺🇸 FDA

Intelligence · Patent portfolio

Iovance Biotherapeutics Patents

Full USPTO pharma patent portfolio for Iovance Biotherapeutics — grant dates, expiration, and drug cross-links.

Patents
94
Expiring ≤24m
0

Quick answer

Iovance Biotherapeutics has 94 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 2

  1. US 12343380

    Expansion of TILs utilizing AKT pathways inhibitors

    Expires Mon Jun 26 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12280140

    Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy

    Expires Mon Apr 17 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12233075

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Feb 20 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12230378

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12230379

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12226434

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Feb 13 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12194061

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 09 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12188048

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jan 02 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12170134

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Dec 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12159700

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12121541

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Oct 17 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12104172

    Processes for generating TIL products enriched for tumor antigen-specific t-cells

    Expires Mon Sep 26 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12031157

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12023355

    Programmed death 1 ligand 1 (PD-L1) binding proteins and methods of use thereof

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12024718

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jun 27 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 11998568

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 30 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 11981921

    TIL expansion processes using specific cytokine combinations and/or AKTi treatment

    Expires Mon May 09 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 11975028

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon May 02 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 11969444

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Apr 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 11939596

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 11865140

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 11866688

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jan 04 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 11857573

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Dec 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 11819517

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Expires Mon Nov 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 11713446

    Processes for generating TIL products enriched for tumor antigen-specific T-cells

    Expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 11667890

    Engineered artificial antigen presenting cells for tumor infiltrating lymphocyte expansion

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 11631483

    Systems and methods for coordinating manufacturing of cells for patient-specific immunotherapy

    Expires Mon Apr 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 11541077

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 11529372

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 11517592

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 11433097

    Methods of using tumor infiltrating lymphocytes in double-refractory melanoma

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 11401507

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 11384337

    Closed process for expansion and gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Jul 07 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 11369637

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 23 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 11364266

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 16 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 11357841

    Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

    Expires Mon Jun 09 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 11351199

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 11351197

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 11351198

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 11344581

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 11344580

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 11344579

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 11337998

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 11311578

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Apr 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 11304979

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 11304980

    Restimulation of cryopreserved tumor infiltrating lymphocytes

    Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 11291687

    Processes for production of tumor infiltrating lymphocytes and uses of same in immunotherapy

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 11293009

    Remnant tumor infiltrating lymphocytes and methods of preparing and using the same

    Expires Mon Mar 31 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Iovance Biotherapeutics have?

94 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Iovance Biotherapeutics patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.